-
公开(公告)号：WO2021019472A1
公开(公告)日：2021-02-04
申请号：PCT/IB2020/057172
申请日：2020-07-29
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： HIRANO, Naoto , SUGATA, Kenji , SASO, Kayoko
IPC: C12N15/867 , A61K35/17 , A61P35/00 , C07K14/725
Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.
-
公开(公告)号：WO2020178741A1
公开(公告)日：2020-09-10
申请号：PCT/IB2020/051810
申请日：2020-03-03
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： HIRANO, Naoto , MURATA, Kenji , SASO, Kayoko
IPC: C12N15/62 , A61K31/675 , A61K31/7076 , A61K35/12 , A61K35/17 , A61K38/20 , A61P35/00 , C07F9/6584 , C07K14/705 , C07K14/725 , C07K14/74 , C07K19/00 , C12N15/113 , C12N15/12 , C12N15/55 , C12N15/867 , C12N5/078 , C12N5/0783 , C12N5/10 , G01N33/566 , A61K31/7088 , A61K31/713 , C07K14/7051 , C07K14/70596 , C07K2319/03 , C07K2319/70 , C12N15/1138 , C12N15/86 , C12N2310/14 , C12N2740/13043 , C12N9/6494
Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.
-
公开(公告)号：WO2020146946A1
公开(公告)日：2020-07-23
申请号：PCT/CA2020/050042
申请日：2020-01-16
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： BROKX, Richard , MASON, Jacqueline M. , BRAY, Mark R.
IPC: C07K16/28 , A61K39/395 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , C12N15/13 , C12P21/08
Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation. This invention can also be used to modulate osteoclast differentiation.
-
公开(公告)号：WO2020118429A1
公开(公告)日：2020-06-18
申请号：PCT/CA2019/051780
申请日：2019-12-10
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： CHO, Young-bin , ISLAM, Mohammad Khairul , JAFFRAY, David Anthony , NORRLINGER, Bernhard Dieter , FARROKHKISH, Makan , HEATON, Robert K.
Abstract: Various embodiments are described herein of radiation systems and methods for monitoring radiation dose are provided for monitoring an amount of radiation in a radiation beam generated by a radiation source for a radiation treatment session, where a radiation sensor is used to provide an actual radiation measurement and an Artificial Neural Network (ANN) engine is used to generate a predicted radiation measurement based on a plurality of feature values for features including radiation field segments from the radiation treatment plan data for the radiation treatment session. The difference between the actual radiation measurement and the predicted radiation measurement is used to determine whether the radiation system is operating in a predetermined safe operation range.
-
45.发明申请
公开(公告)号：WO2019095056A1
公开(公告)日：2019-05-23
申请号：PCT/CA2018/051443
申请日：2018-11-14
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： NANTHAKUMAR, Kumaraswamy
IPC: A61K31/4178 , A61K31/422 , A61P9/00 , C07D405/12 , C07D413/12
Abstract: The present disclosure relates to methods for the chronic treatment of dyssynchronous cardiac dysfunction (including non-arrhythmia cardiac dysfunction such as heart failure, cardiomyopathy, viral myocarditis, ischemia induced cardiomyopathy, ischemia, chemotheraphy, pacing induced cardiomyopathy or ion channel mutation related dysfunction) and for the prevention or treatment of diseases or conditions associated with dyssynchronous cardiac dysfunction. The method comprises chronically administering to a patient an effective amount of dantrolene, or derivative or analogs thereof (such as azumolene).
-
Patent Agency Ranking
公开(公告)号：WO2019046949A1
公开(公告)日：2019-03-14
申请号：PCT/CA2018/051086
申请日：2018-09-07
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： MASON, Jacqueline M. , BRAY, Mark R. , MAK, Tak Wah , FLETCHER, Graham
IPC: A61K31/5377 , A61K39/395 , A61P35/00 , C07D413/10
Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
-
47.发明申请
公开(公告)号：WO2019018942A1
公开(公告)日：2019-01-31
申请号：PCT/CA2018/050914
申请日：2018-07-27
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： LI, Ren-Ke
Abstract: The present disclosure relates to a biocompatible, electrically conductive biomaterial capable of carrying the electrical potential of a cardiac impulse. The biomaterial comprises a conductive polymer and a biocompatible component. The conductive polymer comprising an aminomethoxybenzoic acid (AMBA) polymer. The present disclosure also relates to treatments, uses and devices using the biocompatible, electrically conductive biomaterial.
-
公开(公告)号：WO2018032088A2
公开(公告)日：2018-02-22
申请号：PCT/CA2017/000192
申请日：2017-08-17
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： NGUYEN, Thuy-Linh , OHASHI, Pamela S. , CROME, Sarah
IPC: A61P35/00
Abstract: There is described herein methods for improving tumor infiltrating lymphocyte (TIL) therapy by limiting the effect of innate lymphoid cells (ILCs) thereon. For example, in an aspect, there is provided a method of treating cancer in a patient in need thereof, comprising inhibiting the suppressive effect of CD56 + CD3 - innate lymphoid cells (ILCs) on tumor infiltrating lymphocyte (TIL) propagation or expansion.
Abstract translation: 本文描述了通过限制其上的先天性淋巴细胞（ILC）的作用来改善肿瘤浸润性淋巴细胞（TIL）治疗的方法。 例如，在一个方面，提供了在有需要的患者中治疗癌症的方法，包括抑制CD56 + CD3 - 天然淋巴样细胞的抑制作用（ ILCs）对肿瘤浸润淋巴细胞（TIL）增殖或扩增的影响。
-
公开(公告)号：WO2018007922A3
公开(公告)日：2018-01-11
申请号：PCT/IB2017/053984
申请日：2017-06-30
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： LIU, Yue , NIJJAR, Tarlochan S. , CHAKRABARTTY, Avijit , HIGAKI, Jeffrey N
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：WO2017214718A3
公开(公告)日：2017-12-21
申请号：PCT/CA2017/050713
申请日：2017-06-09
Applicant: UNIVERSITY HEALTH NETWORK , ST. MICHAEL'S HOSPITAL
Inventor： ZARRINE-AFSAR, Arash , GINSBERG, Howard Joeseph , WOOLMAN, Michael
Abstract: Methods and systems are provided for ionizing molecules for the purpose of analysis by mass spectrometry, in which gaseous material from a sample substrate is generated using laser desorption. The laser is provided having a pulse range of about 1-1000 picoseconds to produce the gaseous material. The gaseous material is heated to generate ions from the molecules present in the gaseous material where the amount of heat that is applied is in the temperature range of 45 °C to 250 °C and the applied heat results in soft ionization of the molecules. The ionized molecules are transported to a mass spectrometer for analysis.
-
-
-
-
-
-
-
-
-
Search Results
1331
records
(took 0.066 seconds)
